Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet. 2017;390(10089):73–84.

Article  PubMed  Google Scholar 

Danve A, Deodhar A. Axial spondyloarthritis in the USA: diagnostic challenges and missed opportunities. Clin Rheumatol. 2019;38(3):625–34.

Article  PubMed  Google Scholar 

Reveille JD, Witter JP, Weisman MH. Prevalence of axial spondylarthritis in the United States: estimates from a cross-sectional survey. Arthritis Care Res (Hoboken). 2012;64(6):905–10.

Article  PubMed  Google Scholar 

Strand V, Singh JA. Patient burden of axial spondyloarthritis. J Clin Rheumatol. 2017;23(7):383–91.

Article  PubMed  PubMed Central  Google Scholar 

Magrey M, Walsh JA, Flierl S, Howard RA, Calheiros RC, Wei D, et al. The international map of axial spondyloarthritis survey: a US patient perspective on diagnosis and burden of disease. ACR Open Rheumatol. 2023;5(5):264–76.

Article  PubMed  PubMed Central  Google Scholar 

Ogdie A, Hwang M, Veeranki P, Portelli A, Sison S, Shafrin J, et al. Association of health care utilization and costs with patient-reported outcomes in patients with ankylosing spondylitis. J Manag Care Spec Pharm. 2022;28(9):1008–20.

PubMed  Google Scholar 

Walsh JA, Song X, Kim G, Park Y. Healthcare utilization and direct costs in patients with ankylosing spondylitis using a large US administrative claims database. Rheumatol Ther. 2018;5(2):463–74.

Article  PubMed  PubMed Central  Google Scholar 

van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27(4):361–8.

Article  PubMed  Google Scholar 

Rudwaleit M, van der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J, et al. The development of assessment of spondyloarthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68(6):777–83.

Article  CAS  PubMed  Google Scholar 

López-Medina C, Ramiro S, van der Heijde D, Sieper J, Dougados M, Molto A. Characteristics and burden of disease in patients with radiographic and non-radiographic axial spondyloarthritis: a comparison by systematic literature review and meta-analysis. RMD Open. 2019;5(2):e001108.

Article  PubMed  PubMed Central  Google Scholar 

Hunter T, Sandoval D, Booth N, Holdsworth E, Deodhar A. Comparing symptoms, treatment patterns, and quality of life of ankylosing spondylitis and non-radiographic axial spondyloarthritis patients in the USA: findings from a patient and rheumatologist survey. Clin Rheumatol. 2021;40(8):3161–7.

Article  PubMed  PubMed Central  Google Scholar 

Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82(1):19–34.

Article  PubMed  Google Scholar 

Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2019;71(10):1599–613.

Article  PubMed  PubMed Central  Google Scholar 

Lilly receives U.S. FDA approval for Taltz® (ixekizumab) for the treatment of active ankylosing spondylitis (radiographic axial spondyloarthritis). https://investor.lilly.com/news-releases/news-release-details/lilly-receives-us-fda-approval-taltzr-ixekizumab-treatment. Accessed 27 Nov 2023.

Lilly's Taltz® (ixekizumab) is the first IL-17A antagonist to receive U.S. FDA approval for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA). https://investor.lilly.com/news-releases/news-release-details/lillys-taltzr-ixekizumab-first-il-17a-antagonist-receive-us-fda. Accessed 27 Nov 2023.

Dougados M, Wei JC, Landewé R, Sieper J, Baraliakos X, Van den Bosch F, et al. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). Ann Rheum Dis. 2020;79(2):176–85.

Article  CAS  PubMed  Google Scholar 

Deodhar A, van der Heijde D, Gensler LS, Kim TH, Maksymowych WP, Østergaard M, et al. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. Lancet. 2020;395(10217):53–64.

Article  CAS  PubMed  Google Scholar 

Braun J, Kiltz U, Deodhar A, Tomita T, Dougados M, Bolce R, et al. Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST. RMD Open. 2022;8(2):e002165.

Article  PubMed  PubMed Central  Google Scholar 

Danve A, Deodhar A. Treatment of axial spondyloarthritis: an update. Nat Rev Rheumatol. 2022;18(4):205–16.

Article  PubMed  Google Scholar 

Yu C-L, Yang C-H, Chi C-C. Drug survival of biologics in treating ankylosing spondylitis: a systematic review and meta-analysis of real-world evidence. BioDrugs. 2020;34(5):669–79.

Article  CAS  PubMed  Google Scholar 

Griffiths H, Smith T, Mack C, Leadbetter J, Butcher B, Acar M, et al. Persistence to biologic therapy among patients with ankylosing spondylitis: an observational study using the OPAL dataset. J Rheumatol. 2022;49(2):150–6.

Article  CAS  PubMed  Google Scholar 

Sieper J, Deodhar A, Marzo-Ortega H, Aelion JA, Blanco R, Jui-Cheng T, et al. Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 study. Ann Rheum Dis. 2017;76(3):571–92.

Article  CAS  PubMed  Google Scholar 

Moral E, Plasencia C, Navarro-Compán V, Salcedo DP, Jurado T, Tornero C, et al. AB0657 Discontinuation of anti-TNF therapy in patients with axial spondyloarthritis in clinical practice: prevalence and causes. Ann Rheum Dis. 2016;75(2):1129.

Google Scholar 

Juanola X, Ramos MJM, Belzunegui JM, Fernández-Carballido C, Gratacós J. Treatment failure in axial spondyloarthritis: insights for a standardized definition. Adv Ther. 2022;39(4):1490–501.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Navarro-Compan V, Plasencia-Rodriguez C, de Miguel E, Diaz Del Campo P, Balsa A, Gratacos J. Switching biological disease-modifying antirheumatic drugs in patients with axial spondyloarthritis: results from a systematic literature review. RMD Open. 2017;3(2): e000524.

Article  PubMed  PubMed Central  Google Scholar 

Yi E, Dai D, Piao OW, Zheng JZ, Park Y. Health care utilization and cost associated with switching biologics within the first year of biologic treatment initiation among patients with ankylosing spondylitis. J Manag Care Spec Pharm. 2021;27(1):27–36.

PubMed  Google Scholar 

Yeaw J, Watson C, Fox KM, Schabert VF, Goodman S, Gandra SR. Treatment patterns following discontinuation of adalimumab, etanercept, and infliximab in a US managed care sample. Adv Ther. 2014;31(4):410–25.

Article  CAS  PubMed  Google Scholar 

Le QA, Kang JH, Lee S, Delevry D. Cost-effectiveness of treatment strategies with biologics in accordance with treatment guidelines for ankylosing spondylitis: a patient-level model. J Manag Care Spec Pharm. 2020;26(10):1219–31.

PubMed  Google Scholar 

Dougados M, Lucas J, Desfleurs E, Claudepierre P, Goupille P, Ruyssen-Witrand A, et al. Factors associated with the retention of secukinumab in patients with axial spondyloarthritis in real-world practice: results from a retrospective study (FORSYA). RMD Open. 2023;9(1):e002802.

Article  PubMed  PubMed Central  Google Scholar 

Chabra S, Gill BJ, Gallo G, Zhu D, Pitou C, Payne CD, et al. Ixekizumab citrate-free formulation: results from two clinical trials. Adv Ther. 2022;39(6):2862–72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chabra S, Birt J, Bolce R, Lisse J, Malatestinic WN, Zhu B, et al. Satisfaction with the injection experience of a new, citrate-free formulation of ixekizumab. Adv Ther. 2024;41(4):1672–84.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marzo-Ortega H, Navarro-Compán V, Akar S, Kiltz U, Clark Z, Nikiphorou E. The impact of gender and sex on diagnosis, treatment outcomes and health-related quality of life in patients with axial spondyloarthritis. Clin Rheumatol. 2022;41(11):3573–81.

Article  PubMed  PubMed Central